Invariant Natural Killer T Cells is under clinical development by Beijing Gene Key Life Technology and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Invariant Natural Killer T Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Invariant Natural Killer T Cells overview
The therapeutic candidate is under development for the treatment of relapsed or advanced hepatocellular carcinoma. It comprises of adoptive autologous invariant V alpha natural killer T cells. It is administered through intravenous route.
Beijing Gene Key Life Technology overview
Beijing Gene Key Life Technology is engaged in research and development of immune cell product technology and therapies for the treatment of solid tumors. The company is headquartered in Beijing City, Beijing, China.
For a complete picture of Invariant Natural Killer T Cells’s drug-specific PTSR and LoA scores, buy the report here.